Comparing the effectiveness of the drugs between Carbetocin and Oxytocin in the prevention of heavy blood loss during normal vaginal delivery
Phase 4
Not yet recruiting
- Conditions
- Health Condition 1: O720- Third-stage hemorrhage
- Registration Number
- CTRI/2024/02/062430
- Lead Sponsor
- Dr Monisha S
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
SINGLETON PREGNANCY
TERM(37 TO 40 WEEKS OF GESTATION)
VAGINAL DELIVERY
Exclusion Criteria
AGE ABOVE 35 YEARS
PREVIOUS LOWER SEGMENT CAESAREAN SECTION
INSTRUMENTAL VAGINAL DELIVERY INCLUDING FORCEPS OR VACUUM ASSISTED
COMPLETE PERINEAL TEAR DURING NORMAL VAGINAL DELIVERY
HIGH RISK PREGNANCIES INCLUDING
ANTEPARTUM HEMORRHAGE
PLACENTA PREVIA
ABRUPTIO PLACENTA
PIH
PRE ECAMPSIA
ECLAMPSIA
GDM
MULTIPLE PREGNANCIES
POLYHYDRAMNIOS
MACROSOMIA
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Carbetocin's action in preventing postpartum hemorrhage compared to Oxytocin?
How does Carbetocin's efficacy in preventing third-stage hemorrhage compare to standard-of-care Oxytocin in vaginal deliveries?
Are there specific biomarkers that can predict maternal response to Carbetocin versus Oxytocin in postpartum hemorrhage prevention?
What are the known adverse events associated with Carbetocin use during labor and how do they compare to Oxytocin?
What alternative uterotonic agents or combination therapies are being explored for postpartum hemorrhage prevention alongside Carbetocin and Oxytocin?